These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35754954)

  • 1. The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review.
    Chan GH
    Front Aging Neurosci; 2022; 14():895430. PubMed ID: 35754954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
    Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
    Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
    Salles PA; Liao J; Shuaib U; Mata IF; Fernandez HH
    J Parkinsons Dis; 2022; 12(6):1703-1725. PubMed ID: 35662127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis.
    Artusi CA; Dwivedi AK; Romagnolo A; Pal G; Kauffman M; Mata I; Patel D; Vizcarra JA; Duker A; Marsili L; Cheeran B; Woo D; Contarino MF; Verhagen L; Lopiano L; Espay AJ; Fasano A; Merola A
    JAMA Netw Open; 2019 Feb; 2(2):e187800. PubMed ID: 30707228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep brain stimulation for monogenic Parkinson's disease: a systematic review.
    Kuusimäki T; Korpela J; Pekkonen E; Martikainen MH; Antonini A; Kaasinen V
    J Neurol; 2020 Apr; 267(4):883-897. PubMed ID: 30659355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease.
    Pal GD; Hall D; Ouyang B; Phelps J; Alcalay R; Pauciulo MW; Nichols WC; Clark L; Mejia-Santana H; Blasucci L; Goetz CG; Comella C; Colcher A; Gan-Or Z; Rouleau GA; Marder K;
    Mov Disord Clin Pract; 2016; 3(5):465-471. PubMed ID: 27709117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep Brain Stimulation in Patients With Mutations in Parkinson's Disease-Related Genes: A Systematic Review.
    de Oliveira LM; Barbosa ER; Aquino CC; Munhoz RP; Fasano A; Cury RG
    Mov Disord Clin Pract; 2019 Jun; 6(5):359-368. PubMed ID: 31286005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view.
    Salles PA; Mata IF; Fernandez HH
    Parkinsonism Relat Disord; 2021 Jul; 88():51-57. PubMed ID: 34119931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study.
    Georgiev D; Delalić S; Zupančič Križnar N; Socher A; Gurevich T; Trošt M
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
    Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
    Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Liu XD; Bao Y; Liu GJ
    Front Neurol; 2019; 10():934. PubMed ID: 31507529
    [No Abstract]   [Full Text] [Related]  

  • 16. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile.
    Leta V; Dafsari HS; Sauerbier A; Metta V; Titova N; Timmermann L; Ashkan K; Samuel M; Pekkonen E; Odin P; Antonini A; Martinez-Martin P; Parry M; van Wamelen DJ; Ray Chaudhuri K
    J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Fernández-Rodríguez B; Dupouy J; Harroch E; Fabre-Delcros MH; Barthélémy C; Loubière P; Barange K; Brefel-Courbon C; Rascol O; Ory-Magne F
    Rev Neurol (Paris); 2021 Oct; 177(8):919-923. PubMed ID: 34154827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review.
    Boura I; Haliasos N; Giannopoulou ΙA; Karabetsos D; Spanaki C
    Mov Disord Clin Pract; 2021 Jul; 8(5):750-757. PubMed ID: 34307748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.
    Over L; Brüggemann N; Lohmann K
    J Neuromuscul Dis; 2021; 8(3):341-356. PubMed ID: 33459660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.